Janux Therapeutics Inc (NASDAQ:JANX) price on Thursday, February 06, fall -8.89% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $40.68.
A look at the stock’s price movement, the close in the last trading session was $44.65, moving within a range at $40.5 and $44.825. The beta value (5-Year monthly) was 3.517. Turning to its 52-week performance, $71.71 and $7.81 were the 52-week high and 52-week low respectively. Overall, JANX moved -23.95% over the past month.
Janux Therapeutics Inc’s market cap currently stands at around $2.35 billion, with investors looking forward to this quarter’s earnings report slated for in March.
The average forecast suggests down to a -80.09% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 11.03M, representing a 36.46% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that JANX is a 100% Sell. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 2 recommend JANX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
JANX’s current price about -6.26% and -20.28% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 39.42, while 7-day volatility ratio is 8.73% and 8.83% in the 30-day chart. Further, Janux Therapeutics Inc (JANX) has a beta value of 3.16, and an average true range (ATR) of 3.58. Analysts have given the company’s stock an average 52-week price target of $69.5, forecast between a low of $42 and high of $100. Looking at the price targets, the low is -3.24% off current price level while to achieve the yearly target high, price needs to move -145.82%. Nonetheless, investors will most likely welcome a -70.85% jump to $69.5 which is the analysts’ median price.
If we refocus on Janux Therapeutics Inc (NASDAQ:JANX), historical trading data shows that trading volumes averaged 0.98 over the past 10 days and 1.17 million over the past 3 months. The company’s latest data on shares outstanding shows there are 52.34 million shares.
The 17.29% of Janux Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 78.63% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 8.55 million on 2025-01-15, giving us a short ratio of 8.41. The data shows that as of 2025-01-15 short interest in Janux Therapeutics Inc (JANX) stood at 2602.9999999999995 of shares outstanding, with shares short rising to 6.41 million registered in 2024-12-13. Current price change has pushed the stock -24.02% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the JANX stock continues to rise going into the next quarter.
